Aβ Oligomer Concentration in Mouse and Human Brain and Its Drug-induced Reduction Ex vivo

Overview

Journal Cell Rep Med

Publisher Cell Press

Specialties Biology
General Medicine

Date 2022 May 18

PMID 35584626

Authors

Bettina Kass

Sarah Schemmert

Christian Zafiu

Marlene Pils

Oliver Bannach

Janine Kutzsche

Tuyen Bujnicki

Dieter Willbold

Affiliations

Soon will be listed here.

Abstract

The elimination of amyloid beta (Aβ) oligomers is a promising strategy for therapeutic drug development of Alzheimer's disease (AD). AD mouse models that develop Aβ pathology have been used to demonstrate in vivo efficacy of compounds that later failed in clinical development. Here, we analyze the concentration and size distribution of Aβ oligomers in different transgenic mouse models of AD and in human brain samples by surface-based fluorescence intensity distribution analysis (sFIDA), a highly sensitive method for detecting and quantitating protein aggregates. We demonstrate dose- and time-dependent oligomer elimination by the compound RD2 in mouse and human AD brain homogenates as sources of native Aβ oligomers. Such ex vivo target engagement analyses with mouse- and human-brain-derived oligomers have the potential to enhance the translational value from pre-clinical proof-of-concept studies to clinical trials.

Citing Articles

α-Synuclein fibrils enhance HIV-1 infection of human T cells, macrophages and microglia.

Olari L, Liu S, Arnold F, Kuhlwein J, Gil Miro M, Updahaya A Nat Commun. 2025; 16(1):813.

PMID: 39827271 PMC: 11742913. DOI: 10.1038/s41467-025-56099-z.

Elevated Aβ aggregates in feces from Alzheimer's disease patients: a proof-of-concept study.

Pils M, Dybala A, Schaffrath A, Rehn F, Kutzsche J, Blomeke L Alzheimers Res Ther. 2024; 16(1):223.

PMID: 39402637 PMC: 11472473. DOI: 10.1186/s13195-024-01597-3.

PEGylated pH-Responsive Liposomes for Enhancing the Intracellular Uptake and Cytotoxicity of Paclitaxel in MCF-7 Breast Cancer Cells.

Nijhawan H, Shyamsundar P, Prabhakar B, Yadav K AAPS PharmSciTech. 2024; 25(7):216.

PMID: 39289249 DOI: 10.1208/s12249-024-02930-7.

IAPP - oligomerisation levels in plasma of people with type 2 diabetes.

Rehn F, Kraemer-Schulien V, Bujnicki T, Bannach O, Tschoepe D, Stratmann B Sci Rep. 2024; 14(1):19556.

PMID: 39174611 PMC: 11341561. DOI: 10.1038/s41598-024-70255-3.

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology.

Blomeke L, Rehn F, Kraemer-Schulien V, Kutzsche J, Pils M, Bujnicki T Alzheimers Dement (Amst). 2024; 16(2):e12589.

PMID: 38666085 PMC: 11044868. DOI: 10.1002/dad2.12589.

References

Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jurgens D . Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease. Molecules. 2017; 22(10). PMC: 6151452. DOI: 10.3390/molecules22101693. View

Kamphuis W, Mamber C, Moeton M, Kooijman L, Sluijs J, Jansen A . GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One. 2012; 7(8):e42823. PMC: 3418292. DOI: 10.1371/journal.pone.0042823. View

Jahan M, Nag S, Krasikova R, Weber U, Muhs A, Pfeifer A . Fluorine-18 labeling of three novel D-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography. Nucl Med Biol. 2011; 39(3):315-23. DOI: 10.1016/j.nucmedbio.2011.09.008. View

van Groen T, Kadish I, Wiesehan K, Funke S, Willbold D . In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. ChemMedChem. 2008; 4(2):276-82. DOI: 10.1002/cmdc.200800289. View

Rzepecki P, Nagel-Steger L, Feuerstein S, Linne U, Molt O, Zadmard R . Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands. J Biol Chem. 2004; 279(46):47497-505. DOI: 10.1074/jbc.M405914200. View

Rupp N, Wegenast-Braun B, Radde R, Calhoun M, Jucker M . Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol Aging. 2010; 32(12):2324.e1-6. DOI: 10.1016/j.neurobiolaging.2010.08.014. View

Lee M, Borchelt D, Kim G, Thinakaran G, Slunt H, Ratovitski T . Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med. 1997; 3(7):756-60. DOI: 10.1038/nm0797-756. View

Dominguez-Del-Toro E, Rodriguez-Moreno A, Porras-Garcia E, Sanchez-Campusano R, Blanchard V, Laville M . An in vitro and in vivo study of early deficits in associative learning in transgenic mice that over-express a mutant form of human APP associated with Alzheimer's disease. Eur J Neurosci. 2004; 20(7):1945-52. DOI: 10.1111/j.1460-9568.2004.03643.x. View

Funke S, van Groen T, Kadish I, Bartnik D, Nagel-Steger L, Brener O . Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice. ACS Chem Neurosci. 2012; 1(9):639-48. PMC: 3368690. DOI: 10.1021/cn100057j. View

10.

Herrmann Y, Bujnicki T, Zafiu C, Kulawik A, Kuhbach K, Peters L . Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies. Clin Chim Acta. 2017; 466:152-159. DOI: 10.1016/j.cca.2017.01.010. View

11.

Jager S, Leuchtenberger S, Martin A, Czirr E, Wesselowski J, Dieckmann M . alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation. J Neurochem. 2009; 111(6):1369-82. DOI: 10.1111/j.1471-4159.2009.06420.x. View

12.

Thal D, Walter J, Saido T, Fandrich M . Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease. Acta Neuropathol. 2014; 129(2):167-82. DOI: 10.1007/s00401-014-1375-y. View

13.

Miao J, Xu F, Davis J, Otte-Holler I, Verbeek M, Van Nostrand W . Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol. 2005; 167(2):505-15. PMC: 1603574. DOI: 10.1016/s0002-9440(10)62993-8. View

14.

. 2020 Alzheimer's disease facts and figures. Alzheimers Dement. 2020; . DOI: 10.1002/alz.12068. View

15.

Hadjichrysanthou C, Evans S, Bajaj S, Siakallis L, McRae-McKee K, de Wolf F . The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. Alzheimers Res Ther. 2020; 12(1):74. PMC: 7293779. DOI: 10.1186/s13195-020-00636-z. View

16.

Gulyas B, Spenger C, Beliczai Z, Gulya K, Kasa P, Jahan M . Distribution and binding of 18F-labeled and 125I-labeled analogues of ACI-80, a prospective molecular imaging biomarker of disease: a whole hemisphere post mortem autoradiography study in human brains obtained from Alzheimer's disease patients. Neurochem Int. 2011; 60(2):153-62. DOI: 10.1016/j.neuint.2011.10.010. View

17.

van Groen T, Schemmert S, Brener O, Gremer L, Ziehm T, Tusche M . The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Sci Rep. 2017; 7(1):16275. PMC: 5701182. DOI: 10.1038/s41598-017-16565-1. View

18.

Schartmann E, Schemmert S, Ziehm T, Leithold L, Jiang N, Tusche M . Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease. Eur J Pharm Sci. 2017; 114:93-102. DOI: 10.1016/j.ejps.2017.12.005. View

19.

Hong W, Wang Z, Liu W, OMalley T, Jin M, Willem M . Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer's disease brain. Acta Neuropathol. 2018; 136(1):19-40. PMC: 6647843. DOI: 10.1007/s00401-018-1846-7. View

20.

Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F . Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012; 7(2):e32014. PMC: 3280222. DOI: 10.1371/journal.pone.0032014. View